0 CHECKOUT

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2015

  • ID: 3293067
  • May 2015
  • 151 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • Biocon Limited
  • Celltrion, Inc.
  • Innovent Biologics, Inc.
  • Mabion SA
  • Panacea Biotec Limited
  • MORE

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2015

Summary

This, ‘Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2015’, provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • Biocon Limited
  • Celltrion, Inc.
  • Innovent Biologics, Inc.
  • Mabion SA
  • Panacea Biotec Limited
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Ankylosing Spondylitis (Bekhterev's Disease) Overview
Therapeutics Development
Pipeline Products for Ankylosing Spondylitis (Bekhterev's Disease) - Overview
Pipeline Products for Ankylosing Spondylitis (Bekhterev's Disease) - Comparative Analysis
Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics under Development by Companies
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Ankylosing Spondylitis (Bekhterev's Disease) - Products under Development by Companies
Ankylosing Spondylitis (Bekhterev's Disease) - Companies Involved in Therapeutics Development
Amgen Inc.
Avesthagen Limited
BIOCAD
Biocon Limited
Boehringer Ingelheim GmbH
Celgene Corporation
Celltrion, Inc.
Covagen AG
Epirus Biopharmaceuticals, Inc.
Genor BioPharma Co., Ltd.
Inbiopro Solutions Pvt. Ltd.
Innovent Biologics, Inc.
Johnson & Johnson
Lupin Limited
Mabion SA
Momenta Pharmaceuticals, Inc.
Novartis AG
Oncobiologics, Inc.
Panacea Biotec Limited
Pfizer Inc.
Protalix BioTherapeutics, Inc.
Sandoz International GmbH
Shanghai Pharmaceutical Co., Ltd.
Therapeutic Proteins International, LLC
Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
adalimumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
apremilast - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BI-655066 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
COVA-322 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
golimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
golimumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IBI-303 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IBPM-004AM - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IBPM-005IX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
infliximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
infliximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
infliximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
infliximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
infliximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
infliximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INV-17 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
secukinumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
thalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tofacitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ankylosing Spondylitis (Bekhterev's Disease) - Recent Pipeline Updates
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects
Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products
Ankylosing Spondylitis (Bekhterev's Disease) - Product Development Milestones
Featured News & Press Releases
Feb 16, 2015: Hospira launches first biosimilar monoclonal antibody Inflectra (infliximab) in major European markets
Nov 15, 2014: Novartis presents ground-breaking Phase III results showing AIN457 (secukinumab) significant efficacy in ankylosing spondylitis patients
Nov 10, 2014: Novartis to reveal landmark Phase III data for AIN457 (secukinumab) in psoriatic arthritis and ankylosing spondylitis at ACR 2014
Oct 23, 2014: Novartis AIN457 (secukinumab) meets primary endpoint in two Phase III studies in ankylosing spondylitis, a debilitating joint condition of the spine
Jul 09, 2014: Celgene Reports Results from the Phase III POSTURE Study Evaluating Oral OTEZLA in Ankylosing Spondylitis
Sep 11, 2013: Hospira’s Inflectra the first biosimilar monoclonal antibody to be approved in Europe
Jun 27, 2013: Celltrion Healthcare Receives CHMP Positive Opinion For Remsima
May 31, 2013: Celltrion Provides Update On CT-P13 EU Approval Process
Mar 26, 2013: Celltrion Signs KRW88 Billion Contract With Celltrion Healthcare
Dec 14, 2012: Celltrion Signs KRW99 Billion Contract With Celltrion Healthcare
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H1 2015
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Amgen Inc., H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Avesthagen Limited, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by BIOCAD, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biocon Limited, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Boehringer Ingelheim GmbH, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Celgene Corporation, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Celltrion, Inc., H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Covagen AG, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Genor BioPharma Co., Ltd., H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Innovent Biologics, Inc., H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Johnson & Johnson, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Lupin Limited, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Mabion SA, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Momenta Pharmaceuticals, Inc., H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Novartis AG, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Oncobiologics, Inc., H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Panacea Biotec Limited, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Pfizer Inc., H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Protalix BioTherapeutics, Inc., H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Sandoz International GmbH, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Shanghai Pharmaceutical Co., Ltd., H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Therapeutic Proteins International, LLC, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics - Recent Pipeline Updates, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects (Contd..1), H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H1 2015
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Amgen Inc.
Avesthagen Limited
BIOCAD
Biocon Limited
Boehringer Ingelheim GmbH
Celgene Corporation
Celltrion, Inc.
Covagen AG
Epirus Biopharmaceuticals, Inc.
Genor BioPharma Co., Ltd.
Inbiopro Solutions Pvt. Ltd.
Innovent Biologics, Inc.
Johnson & Johnson
Lupin Limited
Mabion SA
Momenta Pharmaceuticals, Inc.
Novartis AG
Oncobiologics, Inc.
Panacea Biotec Limited
Pfizer Inc.
Protalix BioTherapeutics, Inc.
Sandoz International GmbH
Shanghai Pharmaceutical Co., Ltd.
Therapeutic Proteins International, LLC

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Amneal Pharmaceuticals LLC.
  • Amgen Inc.
  • LEO Laboratories Ltd.
  • Pfizer Inc.
  • Roche Diagnostics Ltd.
  • Merck & Co., Inc.
  • Sanofi S.A.